Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FLT3 D835Y |
Therapy | Palbociclib |
Indication/Tumor Type | hematologic cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 D835Y | hematologic cancer | sensitive | Palbociclib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, transformed cells expressing FLT3 D835Y were sensitive to treatment with Ibrance (palbociclib), demonstrating reduced cell viability in culture and tumor growth inhibition in cell line xenograft models (PMID: 30544932). | 30544932 |
PubMed Id | Reference Title | Details |
---|---|---|
(30544932) | Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib. | Full reference... |